



UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2025 P 1344-6
Program	Prior Authorization/Notification
Medication	Apokyn [®] (apomorphine) injection
P&T Approval Date	12/2020, 12/2021, 12/2022, 12/2023, 12/2024, 12/2025
Effective Date	3/1/2026

1. Background:

Apokyn is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) associated with advanced Parkinson’s disease.

Coverage will be provided for members who meet the following criteria.

2. Coverage Criteria^a:

<p>A. <u>Initial Authorization</u></p> <p>1. Apokyn will be approved based on both of the following:</p> <p>a. Diagnosis of Parkinson’s disease</p> <p style="text-align: center;">-AND-</p> <p>b. Used as intermittent treatment for OFF episodes</p> <p style="text-align: center;">Authorization will be issued for 6 months.</p> <p>B. <u>Reauthorization</u></p> <p>1. Apokyn will be approved based on the following criteria:</p> <p>a. Documentation of positive clinical response to Apokyn therapy</p> <p style="text-align: center;">Authorization will be issued for 12 months.</p> <p>^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.</p>

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.



- Supply limits and/or Medical Necessity may be in place.

4. References:

1. Apokyn [package insert]. Rockville, MD: MDD US Operations, LLC; June 2022.

Program	Prior Authorization/Notification - Apokyn (apomorphine) injection
Change Control	
12/2020	New program
12/2021	Annual review with no changes.
12/2022	Annual review with no changes to clinical coverage criteria. Added state mandate footnote and updated reference.
12/2023	Annual review with no changes to coverage criteria.
12/2024	Annual review with no changes to coverage criteria.
12/2025	Annual review with no changes to coverage criteria.